How should I manage a patient with primary pulmonary hypertension on Endobloc T (ambrisentan + tadalafil) who develops diarrhea and auxiliary lymphadenopathy?

Management of Diarrhea and Axillary Lymphadenopathy in a Patient on Endobloc T

The diarrhea and axillary lymphadenopathy in this patient require immediate investigation to rule out serious underlying conditions unrelated to PAH therapy, as these are not recognized adverse effects of ambrisentan-tadalafil combination therapy. While you continue the Endobloc T for pulmonary hypertension management, urgent workup for the new symptoms is essential.

Immediate Diagnostic Approach

Evaluate the Lymphadenopathy

• Size, consistency, mobility, and tenderness of axillary nodes
• Bilateral vs unilateral presentation
• Associated systemic symptoms: fever, night sweats, weight loss
• Skin examination for rashes, lesions, or signs of infection
• Consider imaging (ultrasound or CT) if nodes are >1.5 cm, hard, fixed, or progressively enlarging
• Biopsy if concerning features present (persistent >4 weeks, hard consistency, or systemic symptoms)

Characterize the Diarrhea

• Duration, frequency, consistency (watery vs bloody)
• Associated symptoms: abdominal pain, fever, weight loss
• Infectious workup: stool culture, ova and parasites, Clostridioides difficile toxin
• Inflammatory markers: CBC, CRP, ESR
• Celiac serology and thyroid function if chronic

Critical Differential Considerations

Lymphadenopathy Causes to Exclude

• Infection: HIV, tuberculosis, cat-scratch disease, toxoplasmosis
• Malignancy: lymphoma, metastatic disease (especially breast cancer in axillary region)
• Autoimmune conditions: systemic lupus erythematosus, rheumatoid arthritis (relevant given 34% of PAH patients in trials had connective tissue disease) 1

Diarrhea Etiologies

• Infectious gastroenteritis
• Inflammatory bowel disease
• Celiac disease
• Medication-related (though not typical for ambrisentan-tadalafil)
• Thyroid dysfunction (hyperthyroidism)

PAH Therapy Considerations

Known Adverse Effects of Ambrisentan-Tadalafil

According to FDA labeling, the most common adverse events with combination therapy are 2:

• Peripheral edema (most frequent)
• Headache
• Nasal congestion
• Anemia (requires monitoring)

Diarrhea and lymphadenopathy are NOT recognized adverse effects of this combination therapy 2.

Continue PAH Therapy Unless

• Fluid retention becomes clinically significant (requiring hospitalization for decompensating heart failure) 2
• Hemoglobin drops significantly (>15% decrease below normal) 2
• Patient develops acute pulmonary edema (consider pulmonary veno-occlusive disease) 2
• Drug interactions are identified with new medications 3

Monitoring While Investigating

PAH-Specific Monitoring

• Hemoglobin levels monthly initially, then periodically (ambrisentan causes anemia in 7-10% of patients) 2
• Liver function tests periodically
• Assess for peripheral edema and weight gain
• Functional status: WHO functional class, 6-minute walk distance

Watch for Clinical Worsening

Hospitalization in PAH patients is associated with significant subsequent mortality 4. Monitor for:

• Worsening dyspnea or exercise tolerance
• Signs of right ventricular failure: jugular venous distension, hepatomegaly, ascites
• Syncope or presyncope

Common Pitfalls to Avoid

1. Do not attribute new symptoms to PAH therapy without evidence - these symptoms require independent investigation
2. Do not discontinue effective PAH therapy prematurely - the combination of ambrisentan and tadalafil reduces clinical failure events by 50% 5 and PAH-related hospitalizations by 63% 6
3. Do not overlook connective tissue disease - if not already evaluated, consider screening given the association with PAH 7
4. Do not miss drug interactions - review all medications for CYP3A4 interactions with tadalafil and potential issues with ambrisentan 3

Treatment Algorithm

If investigations reveal:

• Infectious cause: Treat infection appropriately; continue PAH therapy
• Malignancy: Coordinate with oncology; PAH therapy decisions based on prognosis and treatment interactions
• Autoimmune disease: Treat underlying condition; continue PAH therapy (combination therapy effective in CTD-PAH) 7
• No clear etiology after workup: Consider gastroenterology and hematology consultation; continue PAH therapy with close monitoring

The key principle: these symptoms are unlikely related to Endobloc T and require thorough investigation while maintaining effective pulmonary hypertension management unless contraindications develop.